Michael R Liebowitz MD
Professor of Clinical Psychiatry at Columbia University College of Physicians and Surgeons. Research Scientist in the Anxiety Disorders Clinic at New York State Psychiatric Institute.
Join to View Full Profile
14 East 90th StSuite 1aNew York, NY 10128
Phone+1 212-876-9881
Fax+1 212-876-6148
Dr. Liebowitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1975 - 1977
University of Vermont Medical CenterResidency, Psychiatry, 1974 - 1975
Harlem Hospital CenterResidency, Internal Medicine, 1969 - 1971
Yale School of MedicineClass of 1969
Certifications & Licensure
NY State Medical License 1970 - 2026
NJ State Medical License 1977 - 2025
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder Start of enrollment: 2000 Aug 01
- Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder Start of enrollment: 2003 Dec 01
- Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Start of enrollment: 2013 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsEfficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial.Susan L McElroy, Preciosa M Coloma, Benjamin Berger, Anna I Guerdjikova, J Mark Joyce
The International Journal of Eating Disorders. 2023-11-01 - 5 citationsEfficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized...Lenard A Adler, Julie Adams, Jessica Madera-McDonough, Eva Kohegyi, Mary Hobart
Journal of Clinical Psychopharmacology. 2022-06-02 - 52 citationsThe effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-conc...Mark E. Schmidt, Michael R. Liebowitz, Murray B. Stein, Jennifer Grunfeld, Ilse Van Hove
Neuropsychopharmacology. 2021-04-01
Press Mentions
VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94BJuly 23rd, 2020- VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline UpdateJune 29th, 2020
Anxiety Disorders: Living on a Thin LineJune 5th, 2005- Join now to see all
Grant Support
- CBT Augmentation Of Paroxetine For Social AnxietyNational Institute Of Mental Health2003–2006
- CBT Augmentation Of SRI Pharmacotherapy For OCDNational Institute Of Mental Health2000–2004
- Pharmacotherapy Of Social PhobiaNational Institute Of Mental Health1985–2001
- Long Term Treatment Of Social PhobiaNational Institute Of Mental Health1996–2000
- Clomipramine And Behavior Therapy In OCDNational Institute Of Mental Health1997–1999
- Pharmacotherapy Of Social PhobiaNational Institute Of Mental Health1995–1999
- Residual Impairment In Treated OCD PatientsNational Institute Of Mental Health1998
- Chlorimipramine And Behavior Therapy For OCDNational Institute Of Mental Health1992–1993
- Fluoxetine In Adolescent Obsessive Compulsive DisorderNational Institute Of Mental Health1990–1992
- Chlorimipramine And Behavior Therapy For OCDNational Institute Of Mental Health1990–1991
- Psychobiology Of Obsessive-Compulsive DisorderNational Institute Of Mental Health1989–1991
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
